Comprehensive genetic testing for advanced lung cancer
Official title: Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care
Funded at Yale University · NIH-11179330 · Data updated 2026-11-12
This project looks at how using wide genetic testing that checks hundreds of cancer genes might help people with advanced non-small cell lung cancer and influence care decisions and costs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $653,926 |
| NIH project number | 5R01CA280359-03 |
| Project ID | NIH-11179330 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with advanced non-small cell lung cancer receiving care in the United States are the main group whose care patterns and outcomes are studied.
✕Less likely to help
People without advanced lung cancer, those with early-stage disease, or patients whose tumors lack actionable mutations likely would not directly benefit from this work.
What this research studies
If you have advanced lung cancer, researchers will use real-world medical records and claims data to see who gets broad genomic profiling, why doctors order it, and how results change treatment choices. They will combine data from Medicare and other contemporary U.S. datasets to track outcomes, treatment patterns, and costs after testing. The team will apply value-of-information methods to estimate whether doing more research would meaningfully reduce uncertainty and improve decisions about using broad genomic testing. Findings are meant to inform clinicians, patients, insurers, and policymakers about the practical benefits and trade-offs of routine broad genomic testing.
Why it matters
Potential benefit: Could help more patients be matched to targeted treatments and guide decisions about when broad genomic testing is worth using.
How similar studies have gone: Previous work shows broad genomic profiling often finds actionable mutations and can guide targeted therapy, but evidence on long-term outcomes and cost-effectiveness is still evolving.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Gross, Cary P. — Yale University
- Study coordinator: Gross, Cary P.
Related research
Other NIH-funded projects on the same topics.
-
Spatial control of immunogenic cancer killing for locally advanced lung cancer
A new approach uses radiation-triggered nanoparticles to deliver cancer-killing drugs directly to lung tumors while sparing healthy tissue.
-
Predicting how function, thinking, and life quality change in older adults with advanced lung cancer
This project aims to better predict how older adults with advanced non-small cell lung cancer will fare in daily living, thinking, and overall well‑being during treatment.
-
Pathways: a hopeful program to help advanced lung cancer patients pursue personal goals and improve well-being
A brief, hope-based program helps adults with advanced lung cancer stay connected to goals in family, work, and daily life to support mental health and quality of life during treatment.
-
Inhalable treatment for advanced lung cancer using engineered Influenza A virus
This study is testing a new inhalable treatment for lung cancer that has spread, using a specially designed virus to help your body fight the cancer while keeping healthy cells safe, and it’s aimed at improving survival for patients like you.
-
Brief behavioral support to help breathlessness in advanced lung cancer
A multi-site study tests a short behavioral program delivered by nurses to help adults with advanced lung cancer feel less breathless and more able to do daily activities.
-
Pathways: Supporting Mental Health and Quality of Life for People with Advanced Lung Cancer
This project offers a new program called "Pathways" to help people with advanced lung cancer achieve their personal goals and improve their well-being during treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.